(2)
Regulatory News:
CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, today announces that is has obtained a €1.4 million grant as a winner of the Ministry for Industry s Industrial recovery plan Strategic sectors call for projects.
This non-dilutive financing will contribute to the CAP 23 industrialization program that aims to size the production of the Aeson heart for its commercial phase, notably by:
increasing CARMAT s production capacity on its Bois-d Arcy industrial site;
digitalizing this site; and